H. Lundbeck A/S (CPH:HLUN.A)

Market Cap	29.15B
Revenue (ttm)	22.00B
Net Income (ttm)	3.14B
Shares Out	n/a
EPS (ttm)	3.17
PE Ratio	9.27
Forward PE	6.02
Dividend	0.95 (3.52%)
Ex-Dividend Date	Mar 27, 2025

Volume	122,315
Average Volume	93,156
Open	26.30
Previous Close	26.35
Day's Range	25.25 - 26.40
52-Week Range	23.30 - 41.70
Beta	0.27
RSI	44.38
Earnings Date	May 14, 2025

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 5,707
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: HLUN.A

Financial Performance

In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.